Response to Letter Regarding Article, "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT".

Published

Journal Article (Letter)

Full Text

Duke Authors

Cited Authors

  • Bohula, EA; Giugliano, RP; Cannon, CP; Zhou, J; Murphy, SA; White, J; Tershakovec, AM; Blazing, MA; Braunwald, E

Published Date

  • March 29, 2016

Published In

Volume / Issue

  • 133 / 13

Start / End Page

  • e463 -

PubMed ID

  • 27022050

Pubmed Central ID

  • 27022050

Electronic International Standard Serial Number (EISSN)

  • 1524-4539

Digital Object Identifier (DOI)

  • 10.1161/CIRCULATIONAHA.116.020947

Language

  • eng

Conference Location

  • United States